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Background: Colorectal cancer (CRC) represents the third leading cause of cancer-related death in the United
States. Lack of reliable biomarkers remains a critical issue for early detection of CRC. In this study,we investigated
the potential predictive values of circulating prostaglandin (PG) biosynthesis in CRC risk.
Methods: Proﬁles of circulating PG biosynthesis and platelet counts were determined in healthy subjects (n =
16), familial adenomatous polyposis (FAP) patients who were classiﬁed as regular aspirin users (n = 14) or
nonusers (n = 24), and CRC patients with (n = 18) or without FAP history (n = 20). Immunohistochemistry
staining was performed on biopsy samples.
Results: Analysis of circulating PG biosynthesis unexpectedly revealed that CRC progression is accompanied by a
pronounced elevation of circulating thromboxane A2 (TXA2) levels. When a circulating TXA2 level of 1000 pg/mL
was selected as a practical cutoff point, 95% of CRC patients were successfully identiﬁed. Further study suggested
that the TXA2 pathway is constitutively activated during colorectal tumorigenesis and required for anchorage-
independent growth of colon cancer cells.
Conclusions: This study established the importance of the TXA2 pathway in CRC pathophysiology, and laid the
groundwork for introducing a TXA2-targeting strategy to CRC prevention, early detection and management.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Colorectal cancer (CRC) represents the third leading cause of cancer-
related death in the United States (Siegel et al., 2014a,b). Despite majornomatouspolyposis; PGs, pros-
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. This is an open access article underimprovements in preventive strategies and chemotherapeutic regi-
mens, little change in CRC mortality has occurred over the past 50
years, which is at least partly due to late diagnosis (Srivastava et al.,
2001). A lack of reliable biomarkers remains a critical issue for CRC
early detection. Although colonoscopy screening and fecal occult
blood testing have proven to be effective in the early detection of CRC,
patient compliance is still low (deVos et al., 2009). Therefore, an urgent
need exists to identify novel and convenient biomarkers for early detec-
tion of CRC.
Prostaglandins (PGs) and prostaglandin-endoperoxide synthases
(PTGS, cyclooxygenases) have been implicated in various pathological
processes such as inﬂammation, cardiovascular disease and cancer
(Wang and Dubois, 2010). Although pivotal roles for colonic PGs and
PTGS have been well-established in colorectal tumorigenesis
(Castellone et al., 2005; Chulada et al., 2000; Oshima et al., 1996;
Sonoshita et al., 2001), the proﬁles of circulating PG biosynthesis in
CRC remain unclear. Herein, we investigated whether patients at high
risk of developing CRC could be identiﬁed from their levels of circulating
PGs.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Materials, Chemicals, and Reagents
Primary antibodies against human microsomal prostaglandin E
synthase-1 (mPGES1), thromboxane A2 synthase 1 (TBXAS1), and
thromboxane A2 receptor (TBXA2R) were obtained from Cayman
Chemical Company (Ann Arbor, MI). All chemicals were purchased
from Sigma-Aldrich (St Louis, MO) unless otherwise speciﬁed.
2.2. Cell Culture and Transfection
All cell lines used in this study were obtained from the American
Type Culture Collection (ATCC,Manassas, VA) andmaintained following
ATCC instructions. Cells were cytogenetically tested and authenticated
before being frozen. Each vial of frozen cells was thawed and main-
tained for a maximum of 20 passages. For lentiviral transfection, the
jetPEI reagent (Qbiogene, Inc., Montreal, Quebec, Canada)was used, fol-
lowing the manufacturer's instructions. The 29-mer small hairpin RNA
(shRNA) constructs against human TBXA2R and TBXAS1 were obtained
from Open Biosystems, Inc. (Huntsville, AL).
2.3. Anchorage-Independent Growth Assay
In each well of a 6-well plate, cells (8 × 103) were suspended in
Basal Medium Eagle (BME) medium (1 mL, with 10% FBS and 0.33%
agar) and plated over a layer of solidiﬁed BME (3 mL, with 10% FBS
and 0.5% agar). The cultures were incubated in a 37 °C, 5% CO2 incu-
bator for 7 d and colonies in soft agar were counted under a micro-
scope equipped with the Image-Pro Plus software program (Media
Cybernetics, Bethesda, MD).
2.4. Western Blot Analysis
Protein samples (20 μg) were resolved by SDS-PAGE and transferred
to Hybond C nitrocellulose membranes (Amersham Corporation, Ar-
lington Heights, IL). After blocking, the membranes were probed with
primary antibodies (1:1000) overnight at 4 °C. The targeted protein
bands were visualized using an enhanced chemiluminescence reagent
(AmershamCorporation) after hybridizationwith a secondary antibody
conjugated with horseradish peroxidase.
2.5. Clinical Study
2.5.1. Study Design
Volunteers were recruited by the Gastroenterology and Hepatology
group atMayo Clinic, Rochester, Minnesota or from the Gastroenterolo-
gy group at The Afﬁliated Cancer Hospital, Zhengzhou University,
Zhengzhou, China. All clinical studies using human subjects or
human materials were approved by the Mayo Clinic review board or
The afﬁliated Cancer Hospital, Zhengzhou University review board
(#2014xjs28), respectively. Written, informed consent was required
for entry of any patient into this study. Exclusion criteria included ciga-
rette smoking, inﬂammatory bowel diseases, hypertension, a history of
cardiovascular diseases, and pregnancy.
2.5.2. Subjects
Individuals in the healthy control group (n= 16) were normal sub-
jects who underwent colonoscopy screening. Familial adenomatous
polyposis (FAP) patients who reported taking two or more standard
(325 mg) aspirin tablets per week within the previous 12 months
were classiﬁed as regular aspirin users (n = 14) and those reporting
consumption of less aspirin were classiﬁed as aspirin nonusers (n =
24) (Chan et al., 2007). Individuals in the sporadic colorectal cancer
group (n = 20) were patients who were diagnosed with CRC, butwithout a family history of CRC. The gender ratio in each group was ap-
proximately 1:1.
2.5.3. Measurement of Plasma PGs
Brieﬂy, blood was collected from a vein in the arm just inside the
elbow using a 22 gauge needle. Before blood collection, the tourni-
quet was applied about three inches above the selected puncture
site. Venous blood was drawn into a BD vacationer® PST™ plasma
separation tube (#367964, BD Biosciences) containing lithium
heparin. Blood samples were then centrifuged at 2000 ×g for
15 min and the resulting supernatant fraction was designated as
plasma. The measurement of plasma PGs was performed using en-
zyme immunoassay kits from Cayman Chemical Company (Ann
Arbor, MI) following the manufacturer's instructions. Considering
the fact that PGD2, PGF2α, PGI2, and TXA2 are unstable in vivo, we
determined their corresponding primary metabolites in plasma as
follows: 11-beta-PGF2α, 13,14-dihydro-15-keto-PGF2α, 6-keto-
PGF1α, and TXB2.
2.5.4. Measurement of Urinary 11-Dehydro-Thromboxane B2
Urine samples were collected for determination of urinary 11-
dehydro-thromboxane B2 (the major TXB2 metabolite) levels. Samples
were collected fromhealthy (n=8) or CRC patient (n=24) volunteers
recruited from the Gastroenterology group at The Afﬁliated Cancer Hos-
pital, Zhengzhou University, Zhengzhou, China. All clinical studies using
human subjects or human materials were approved by the The
Afﬁliated Cancer Hospital, Zhengzhou University review board
(#2014xjs28). Samples were collected between 8 p.m. and 8 a.m. and
kept in −80 °C. Determination of 11-dehydro-thromboxane B2 was
performed by using an enzyme immunoassay kit (11-dehydro-throm-
boxane B2 EIA Kit, Cayman Chemical item number 519510) following
themanufacturer's instructions. Urinary creatinine levels were detected
by a Creatinine (urinary) Colorimetric Assay Kit (Cayman Chemical item
number 500701) as an index of standardization for 11-dehydro-
thromboxane B2 (Cayman Chemical item number 500701).
2.5.5. Histology and Immunohistochemistry
Surgically resected human colon tissues at all clinical stages
were ﬁxed in 10% formalin overnight at room temperature. For his-
tology, ﬁxed tissues were embedded in parafﬁn, sectioned at 5 μm,
and stained with hematoxylin and eosin (H&E) according to stan-
dard protocols. Immunohistochemistry staining for human
cyclooxygenase-2 (COX-2, #12282, Cell Signaling Technology; di-
lution 1:200), mPGES1 (#160140, Cayman Chemical Company; di-
lution 1:50), TBXAS1 (#160715, Cayman Chemical Company;
dilution 1:50), TBXA2R (#10004452, Cayman Chemical Company;
dilution 1:50), or Ki-67 (RM-9106, Thermo Scientiﬁc, Fremont,
CA; dilution 1:200) was performed using an ABC complex kit (PK-
6100, Vector Laboratories, Burlingame, CA) following the
manufacturer's instructions. Sections were counterstained with
Harris's hematoxylin. For antibody-negative controls, the primary
antibodies were substituted with normal rabbit serum. Immuno-
histochemistry staining intensity was quantiﬁed by calculating
the integrated optical density (IOD, sum) of the area of interest
using the Image Pro-Plus 7.0 software program.
2.6. Statistical Analysis
Statistical analysis was performed using the Prism 5.0 statistical soft-
ware package. Pearson correlation was used to measure the strength of
association between two variables. The Tukey's t-test was used to com-
pare data between two groups. One-way ANOVA and the Bonferroni
correction were used to compare data between three or more groups.
Values are expressed asmeans±S.D. and a p value of b0.05was consid-
ered statistically signiﬁcant.
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3.1. Proﬁles of Circulating PG Biosynthesis in CRC
We ﬁrst analyzed the proﬁles of circulating PG biosynthesis during
CRC progression. The multistep nature of CRC (the so-called normal
epithelial mucosa–adenoma–carcinoma sequence) has been well-
established in FAP patients who universally develop CRC in the absence
of colonic resection (Markowitz and Bertagnolli, 2009). Accordingly, we
recruited FAP patients, and further sub-grouped them based upon path-
ological disease stage. Among the ﬁve major bioactive PGs examined,
TXA2, but not PGE2, was the most abundant PG in plasma from FAP pa-
tients (Fig. 1A). Compared with healthy subjects, the levels of PGD2,
PGE2 and TXA2 were signiﬁcantly elevated in FAP patients, whereas
PGF2α and PGI2 levels did not change signiﬁcantly. Intriguingly, circulat-
ing PGD2 and PGE2 were moderately elevated at the rather late stage
(the adenoma–carcinoma sequence), whereas circulating TXA2 was
dramatically elevated throughout the entire progression of CRC in FAP
patients. For example, in FAP patients who had developed CRC, circulat-
ing TXA2 levels were strikingly increased to 44.3-fold of the normal
level, but circulating PGE2 levels were only enhanced by 6.7-fold.
We next analyzed the proﬁles of circulating PG biosynthesis in spo-
radic CRC patients. Similar results were obtained (Fig. 1B). Of the ﬁve
PGs measured, TXA2 was present at the highest concentration and
only the levels of TXA2 were signiﬁcantly elevated in sporadic CRC pa-
tients compared with healthy subjects. The circulating TXA2 levels in
sporadic CRC patients were 35.9-fold higher than the normal level.
These results indicate that, overall, CRC is accompanied by a pro-
nounced elevation of the level of circulating TXA2.Fig. 1. Circulating PG biosynthesis in CRC progression. (A) Circulating PG levels in healthy
subjects or FAP patients. 1=healthy subjects (n= 16); 2= FAP patients with colonic ad-
enomas (n= 24); and 3 = FAP patients with colonic adenocarcinomas (n = 18). Plasma
samples were collected for measurement of circulating prostaglandin levels using an en-
zyme immunoassay kit (Cayman). Data are presented as means ± S.D. The asterisks indi-
cate a signiﬁcant (**, p b 0.01; ***, p b 0.001) difference compared to the group of healthy
subjects. (B) Proﬁles of circulating PG biosynthesis in healthy subjects (1) or sporadic CRC
(2) patients (n = 20). Data are presented as means ± S.D. The asterisks indicate a signif-
icant (**, p b 0.01; ***, p b 0.001) difference compared to the group of healthy subjects.3.2. Prognostic Value of Circulating TXA2 Levels in CRC
Based on the ﬁndings above, we questioned whether the measure-
ment of circulating TXA2 could predict the risk of developing CRC. To
validate the prognostic value of circulating TXA2 levels in CRC, a test
study was conducted in both FAP and CRC patients. Results indicated
that average circulating TXA2 levels in healthy subjects were 284.2 ±
112.0 pg/mL, whereas the average circulating TXA2 levels in FAP and
CRC patients were 7275.4 ± 4438.6 and 11,328.3 ± 9701.3 pg/mL, re-
spectively (Fig. 2). With a value of 1000 pg/mL selected as a practical
cutoff point to discriminate between CRC high-risk and low-risk groups,
we successfully identiﬁed 21 of 24 FAP patients (88%) and 36 of 38 CRC
patients (95%).
3.3. Pathophysiological Role of the TXA2 Pathway in CRC
To clarify the importance of the TXA2 pathway in CRC, we examined
the expression of the TXA2 receptor (TBXA2R) as well as TXA2 synthase
(TBXAS1, a key enzyme for TXA2 biosynthesis) in biopsy samples
(Fig. 3A). Our immunohistochemistry staining results clearly showed
that both TBXA2R and TBXAS1 were highly expressed in most colonic
polyps or tumors, but not in normal colorectal tissues. Importantly,
TBXA2R and TBXAS1 were co-localized with each other. Consistent
with previous reports regarding the critical role of PGE2 in CRC
(Castellone et al., 2005; Chulada et al., 2000; Oshima et al., 1996;
Sonoshita et al., 2001), we also observed the overexpression of micro-
somal prostaglandin E synthase-1 (mPGES-1, the rate-limiting enzyme
for PGE2 biosynthesis) during CRC progression.
Next, we investigated whether the TXA2 pathway is directly associ-
ated with tumorigenic properties of colon cancer cells. Anchorage-
independent growth ability is an ex vivo indicator and a key character-
istic of the transformed cell phenotype (Hanahan andWeinberg, 2011).
Based on this idea,we conﬁrmed that knockdown of TBXA2R or TBXAS1
in human colorectal cancer cells resulted in fewer colonies being formed
in soft agar compared with control cells (Fig. 3B). Collectively, these
results suggested that blocking the TXA2 pathway might reduce the
malignant potential of colon cancer cells.
3.4. Aspirin Attenuates CRC in FAP Patients by Targeting the TXA2 Pathway
Aspirin shows indisputable promise as a chemopreventive agent
against CRC, but itsmolecular underpinnings remain imperfectly under-
stood (Chan et al., 2007; Algra and Rothwell, 2012; Rothwell et al.,
2010).We hypothesized that aspirin might reduce CRC risk by affecting
the TXA2 pathway. To examine this possibility,we ﬁrst examined the in-
ﬂuence of aspirin intake on circulating PG levels in FAP patients. Results
indicated that regular aspirin use signiﬁcantly decreased the circulatingFig. 2.Prognostic value of circulating TXA2 levels in CRC. To conﬁrm theprognostic value of
circulating TXA2 levels in CRC, a test study was conducted in healthy subjects (n = 16),
FAP patients (n = 24), and CRC patients with (n = 18) or without FAP history (n =
20). Based on a value of 1000 pg/mL, which was selected as a practical cutoff point, 95%
of CRC patients and 88% of FAP patients were successfully identiﬁed.
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Fig. 4. Aspirin reduces CRC risk in FAP patients by targeting the TXA2 pathway. (A) Effects of regular aspirin use on circulating PG biosynthesis in FAP patients. 1 = healthy subjects (n=
16); 2= FAP patients, aspirin nonusers (n= 24); and 3= FAP patients, aspirin users (n= 14). FAP patients who reported taking two ormore standard (325mg) aspirin tablets per week
were classiﬁed as regular aspirin users and those taking less aspirin were deﬁned as aspirin nonusers. Data are presented as means ± S.D. The asterisks (***) indicate a signiﬁcant (p b
0.001) decrease in circulating TXA2 levels associatedwith aspirin intake. (B) Effects of regular aspirin use on the expression patterns of TBXA2R, TBXAS1 andKi-67 in FAP patients. Original
magniﬁcation: 200×. Immunostaining intensities are deﬁned in “Materials andMethods.” (C) Effects of aspirin treatment on TBXA2R and TBXAS1 protein expression in colon cancer cells.
HT29 and HCT116 colon cancer cells were treated with aspirin for 72 h. After treatment, cell lysates were subjected to Western blot analysis as described in “Materials and Methods”.
169H. Li et al. / EBioMedicine 2 (2015) 165–171TXA2 level in FAP patients, but had little effect on the levels of the other
four PGs (Fig. 4A). Due to its very short half-life, TXA2 primarily func-
tions in an autocrine or paracrine manner by binding to the TBXA2R, aFig. 3. Pathophysiological role of the TXA2 pathway in CRC. (A) Immunohistochemical staining o
polyps, adenomas, and adenocarcinomas. For antibody-negative controls, the primary antibodie
pathway is associatedwith tumorigenic properties in human colorectal cancer cells. Knockdown
(upper panels). Mock and knockdown HT29 and HCT116 colon cancer cells were then subjecte
and Methods”. The asterisks (***) indicate a signiﬁcant (p b 0.001) decrease in colony formatiotypical G protein-coupled receptor (GPCR), which might signal platelet
aggregation, cell growth and migration (Rothwell et al., 2010). In this
study, we found that aspirin intake was associated with lowerf TBXA2R, TBXAS1 ormPGES-1 in biopsy samples, which included normal colonicmucosa,
s were substitutedwith normal rabbit serum. Original magniﬁcation: 200×. (B) The TXA2
of TBXA2R or TBXAS1 inHT29 orHCT116 colon cancer cellswas analyzed byWestern blot
d to anchorage-independent growth assays (lower bar graphs) as described in “Materials
n by knockdown HT29 or HCT116 colon cancer cells.
170 H. Li et al. / EBioMedicine 2 (2015) 165–171expression of TBXA2R and TBXAS1, as well as Ki-67, in the epithelial cell
from polyps (Fig. 4B). In addition, aspirin treatment down-regulated
TBXA2R or TBXAS1 expression in colon cancer cells (Fig. 4C).
4. Discussion
In the present study, we provide new evidence showing that the
TXA2 pathway is involved in CRC pathophysiology. Both TBXAS1 and
TBXA2R are highly expressed in colonic neoplastic tissues compared
with normal colonic tissues. Knockdown of either TBXAS1 or TBXA2R
impairs the anchorage-independent growth capability of colon cancer
cells. Importantly, CRC progression is associated with higher circulating
TXA2 levels, which might merit investigation as a predictor of CRC risk.
Although a large body of evidence indicates that PGE2 might be the
predominant PG in cancer, the concept that PGE2 is the only PG involved
in carcinogenesis has long been challenged. For example, PGD2 func-
tions as a pro-resolution mediator in ulcerative colitis (Vong et al.,
2010), and PGI2 is the major PG generated in ovarian epithelial cancer
(Daikoku et al., 2005). Here, we provided novel evidence showing that
CRC progression is accompanied by a pronounced elevation of systemic
TXA2 biosynthesis. Notably, in a mouse model of colon cancer, we ob-
served that blood TXA2 levels in tumor-bearing mice were 17-fold
higher compared to levels in tumor-free mice (Li et al., 2014). Consis-
tent with our ﬁndings, Dovizio et al. also reported that FAP patients' uri-
nary 11-dehydro-TXB2 (one of the major enzymatic metabolites of
TXA2) levels were signiﬁcantly higher compared to those in healthy
subjects (Dovizio et al., 2012).
Platelets have long been suspected to be a major source of TXA2 in
the blood. Based on this idea, we examined platelet counts and found
that it was markedly elevated in FAP patients, especially those who
had already developed CRC. Importantly, platelet countswere positively
correlated with plasma TXA2 levels in FAP patients who were aspirin
nonusers, but was not associated with those patients who used aspirin
regularly (Supplementary Fig. 1). Interestingly, a large body of evidence
supports the idea that speciﬁc inhibition of COX-1, but not COX-2, great-
ly affects systemic TXA2 biosynthesis (Dovizio et al., 2012; McAdam
et al., 1999). Importantly, aspirin exerts its cardio-protective activity
by inhibiting platelet-derived COX-1/TXA2 biosynthesis. Coincidentally,
we conﬁrmed that although overexpressed in FAP patients, COX-2 did
not correlate with plasma TXA2 levels (Supplementary Fig. 2). Notably,
colon cancer cells could trigger platelet activation for TXA2 generation
(Dovizio et al., 2012). All of these ﬁndings, together with our data
here, point to the possibility that platelet-derived TXA2 plays a function-
al role in intestinal tumorigenesis. To this end, further studies such as
examining susceptibility to intestinal polyps inmicewith targeted dele-
tions in either TBXAS1 or TBXA2R are need. Overall, our results indicate
that lowering circulating TXA2 levels or interfering with the TXA2 path-
waymight be a promising strategy for CRC prevention and/or treatment
in the future.
Thrombosis is a common complication in colorectal cancer (CRC)pa-
tients, but its molecular mechanisms remain elusive (Sorensen et al.,
2000). A dynamic balance between pro-thrombotic TXA2 and anti-
thrombotic PGI2 production is generally accepted to be a contributor
to homeostasis of the circulatory system (Cheng et al., 2002). Our data
strongly suggested that elevated circulating TXA2 levels might be linked
with CRC pathophysiology. We also observed that in FAP patients, the
levels of circulating TXA2 were increased by 25.6-fold compared to
healthy subjects, whereas circulating PGI2 levels did not change signiﬁ-
cantly. These ﬁndings implied that FAP patients might also be more
prone to a risk of cardiovascular disease than healthy subjects. Addition-
al clinical studies are needed to examine this possibility.
Detection ofmalignant neoplasms at an early stage offers clinical ad-
vantages (Srivastava et al., 2001). However, the disturbing reality is that
very few reliable biomarkers are available to predict the risk of CRC, one
of themost common anddeadly cancers. Considering the compliance is-
sues associated with optical colonoscopy and the fecal occult blood test,a large amount of effort is being invested in developing reliable but min-
imally invasivemethods for CRC risk screening. Blood is easily sampled by
relatively non-invasive methods, and thus the introduction of a blood-
based test could offer an advantage for enhancing patient compliance
compared to other tests (deVos et al., 2009). Our ﬁndings suggest that cir-
culating TXA2 levelsmight have a potential prognostic or predictive value
for the early detection of CRC. Currently, a prospective collective of plasma
samples from subjects in a CRC screening guideline-eligible population is
underway to further conﬁrm the clinical performance of this biomarker.
Although our ﬁndings are promising for translating circulating
TXA2-based biomarkers from basic research into clinic use, several is-
sues still need to be addressed. For example, our sample size is small,
and data collection is only limited in CRC. Thus more rigorous experi-
ments should be conducted to determine biomarker cut-off optimiza-
tion and calculation of ROC curves. Another issue is how to exclude
the possibility of plasma TXA2 level confounded by platelet aggregation.
To the end, venous blood was carefully collected with anticoagulant in
this study. Although, in theory, the possibility that the plasma TXA2
levels are confounded by platelet aggregation is very low, measurement
of urinary TXA2metabolites such as 11-dehydro TXB2might provide the
best estimate of systemic TXA2 biosynthesis in vivo. Thus, we conﬁrmed
that urinary 11-dehydro TXB2 levels were signiﬁcantly increased in CRC
patients compared to healthy subjects (0.83 ± 0.29 versus 5.83 ± 4.22
ng/mg creatinine, respectively, p b 0.01) (Supplementary Fig. 3).
In summary, this study established the importance of the TXA2 path-
way in CRC pathophysiology, and laid the groundwork for introducing
TXA2-targeted strategy to CRC prevention, early detection and even
management.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2014.12.004.
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